Aug. 17 at 4:53 PM
$ABCL
But this partneship isn’t about one molecule.
AbbVie has been granted full access to AbCellera’s discovery engine to co-develop a range of antibodies, including next-gen T-cell engagers for oncology.
Here’s how it works:
• AbbVie advances a candidate →
$ABCL gets paid
• Drug hits the market →
$ABCL collects royalties
AbCellera basically rented AbbVie an antibody factory… and earns a cut of everything it produces.
Apple doesn’t build every app, and ASML doesn’t make chips, but both platforms are essential to those who do. AbCellera's platform could play a similar role in biotech.
If you’re into this kind of insight, feel free to follow along. I post insights on
$ABCL and my other high-conviction investments reshaping their industries.
